ISSN 2330-717X

Russia Hopes To Boost Vaccine Production At Home And Abroad

By

Russia faces vaccine production challenges to meet the increasing market demand and to make prompt delivery on its current pledges to external countries. As vaccine production and distribution intensifies, rivalry and competition strengthen and the fight for market share and its associated disinformation abound worldwide.

Russian President Vladimir Putin has repeatedly indicated that in order to boost sustainable supplies, the country has to build its domestic production capacity while, at the same time, searching for production partnership in foreign countries.

During a meeting with participants in the nationwide mutual assistance campaign We Are Together on March 4 in the Kremlin, Putin stated that “we still have many problems to deal with, but the fact is we have managed to overcome the challenges at hand far more effectively than many other countries with fairly well-developed healthcare systems.”

According to experts, it would be impossible to cope with the national and global COVID-19 pandemic without them. Indeed, we have every reason to be proud because our vaccines are the safest and most effective in the world.

Russia’s Sputnik V has been registered in some 45 countries. “We have developed the second and third vaccines. And the medicines are very good and meet world standards and levels. Avifavir and some others are rather expensive, but everything is issued free of charge,” he stressed.

“Some matters are not linked with production, although I have repeatedly noted this publicly. There is nothing to be ashamed of, and we need to expand production volumes. We simply never had the required amount of equipment for manufacturing vaccines in such huge volumes. We are expanding production, and we will continue to do so, we will manufacture the vaccines. Production has already been launched outside the Russian Federation, that is, at idle facilities that are available there,” he said.

In his wide-ranging annual media conference held on December 17, Putin explained that as the pandemic spreads, millions of coronavirus vaccine doses would have been produced. “Production of vaccine requires relevant plants, enterprises, and hardware—all that will be scaled up,” he said.

With regard to cooperation with other countries, it will boost the technological capabilities of enterprises to produce the vaccine. Foreign countries will invest their own money into expanding their production capacities and purchasing the corresponding equipment.

“As for cooperation with foreign countries: nothing is stopping us from manufacturing vaccine components at facilities in other countries precisely because we need time to enhance the technological capacities of our vaccine manufacturing enterprises. This does not hinder vaccination in the Russian Federation,” he informed.

“Russia is sending the Sputnik V vaccine abroad despite a deficit of the serum inside the country in order to occupy a leading place in the battle for the pharmaceutical market,” according to Ilya Grashenkov, head of the Center for Regional Development (ura.news/news/1052475760).

What makes the decision of the Kremlin to send domestically produced vaccine abroad so disturbing is that Russian officials have long acknowledged that the Russian pharmaceutical industry lacks the capacity to produce enough vaccine even for domestic use and has sought with some success to get companies abroad to produce it under license.

In the current competitive trend, there are other vaccines such as Oxford/AstraZeneca, Johnson & Johnson and Moderna that have equally become popular in the world. China has approved four vaccines developed by three Chinese companies for general use.

AstraZeneca is a very good company whose vaccine is 61 per cent effective, and our vaccine has an efficiency of 91.6 per cent. Pfizer is being used, about 16 people died in Switzerland following vaccination. Some European countries have stopped administering Pfizer vaccines, due to fatalities.

Pfizer is a global company with a remarkable scientific research base. As well-known, India is home to one of the world’s largest vaccine manufacturers, the Serum Institute of India, as well as other vaccine companies producing candidates. 

Russia works with AstraZeneca after signing a partnership agreement. They proposed a joint project with the Gamaleya Institute to develop a joint product and improve the level of protection ensured by their vaccine. “Only by combining efforts, I am saying this for the second time at this meeting, can we achieve the desired result around the globe. The result we need is of a truly global nature, a global result,” Putin explained with high optimism.

World Health Organization’s representative to Russia, Melita Vujnovic, has said that the coronavirus situation in Russia has been improving, noting further that the “vaccination situation looks optimistic,” especially given the fact that there are three registered vaccines. According to the data from Russia’s Anti-Crisis Center, there are currently 302,281 active coronavirus cases in Russia.

World Health Organization (WHO) has declared the coronavirus outbreak a pandemic since March 2020. Since then, nearly 120 million cases have now been reported to this organization, and more than 2.6 million people have lost their lives.

Kester Kenn Klomegah

Kester Kenn Klomegah

Kester Kenn Klomegah is an independent researcher and a policy consultant on African affairs in the Russian Federation and Eurasian Union. He has won media awards for highlighting economic diplomacy in the region with Africa. Currently, Klomegah is a Special Representative for Africa on the Board of the Russian Trade and Economic Development Council. He enjoys travelling and visiting historical places in Eastern and Central Europe. Klomegah is a frequent and passionate contributor to Eurasia Review.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.